Can clinical and urodynamic parameters predict the occurrence of neutralizing antibodies in therapy failure of intradetrusor onabotulinumtoxin A injections in patients with spinal cord injury?

Table 3 demographic and clinical correlations for antibody formation

	Evaluation	Statistical Test, P-value	Significance
1	Male vs. female	Chi² = 0.710	non-significant
2	PNR vs. SNR	exact Fisher = 0.108	non-significant
3	Motor. + sensor. Complete vs. incomplete lesion (AIS A vs. AIS B, C, D)	Chi² = 0.764	non-significant
4	Motor. complete vs. motor. Incomplete lesion (AIS A, B vs. AIS C, D)	Chi² = 0.406	non-significant
5	Severity of SCI/D	exact Fisher = 0.190	non-significant
6	Age at SCI/D	exact Fisher = 0.257	non-significant
7	Age at first BoNT-A injection	exact Fisher = 0.212	non-significant
8	Age at Non-Response	exact Fisher = 0.529	non-significant
9	Time interval onset SCI/D to first BoNT-A injection	Mann-Whitney-U = 0.788	non-significant
10	Mean time interval first BoNT-A injection to Non-Response	T-Test = 0.015	significant
11	Number of BoNT-A injections Number of BoNT-A injections, Cut off > 5	Mann-Whitney-U = 0.011 Chi² = 0.024	significant significant
12	Median time interval between BoNT-A injections Median time interval between BoNT-A injections, Cut off < 7 month	Mann-Whitney-U = 0.320 Chi² = 0.022	non-significant significant

(PNR Primary non response, SNR Secondary non response, AIS American Spinal Injury Association Impairment Scale, SCI/D Spinal cord injury/disease, BoNT-A botulinum neurotoxin A)

ISSN: 1471-2490